Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab
Margherita Rimini,
Margarida Montes,
Elisabeth Amadeo
et al.
Abstract:INTRODUCTION: Recently, in Hepatocellular carcinoma (HCC) setting, the use of metformin has been associated to a trend toward worse response rate, overall survival and progression free survival in patients who received immunotherapy.
METHODS AND MATERIAL: The study population included individuals from both Eastern and Western regions with a confirmed diagnosis of HCC and receiving first line treatment with atezolizumab plus bevacizumab or lenvatinib. Univariate and multivariate analyses were performed by Cox… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.